Have a feature idea you'd love to see implemented?
Let us know!
XERS Xeris Pharmaceuticals Inc
Price (delayed)
$3.04
Market cap
$453.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.44
Enterprise value
$664.94M
Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
Highlights
The company's revenue rose by 23% YoY and by 3.3% QoQ
The gross profit has grown by 22% YoY
XERS's EPS is down by 4.8% since the previous quarter but it is up by 2.2% year-on-year
XERS's equity is down by 47% since the previous quarter
XERS's quick ratio is down by 24% since the previous quarter and by 6% year-on-year
Key stats
What are the main financial stats of XERS
Market
Valuations
Earnings
Shares outstanding
149.08M
Market cap
$453.21M
Enterprise value
$664.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.55
Revenue
$187.36M
EBIT
-$35.82M
EBITDA
-$23.07M
Free cash flow
-$32.27M
Per share
Balance sheet
Liquidity
EPS
-$0.44
Free cash flow per share
-$0.22
Book value per share
-$0.19
Revenue per share
$1.26
TBVPS
$1.32
Total assets
$321.1M
Total liabilities
$349.43M
Debt
$270.97M
Equity
-$28.32M
Working capital
$71.79M
Debt to equity
-9.57
Current ratio
1.79
Quick ratio
1.21
Net debt/EBITDA
-9.18
Margins
Efficiency
Dividend
EBITDA margin
-12.3%
Gross margin
81.4%
Net margin
-33.7%
Operating margin
-24.1%
Return on assets
-19.2%
Return on equity
N/A
Return on invested capital
-11.4%
Return on capital employed
-15.6%
Return on sales
-19.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XERS stock price
How has the Xeris Pharmaceuticals stock price performed over time
Intraday
-0.65%
1 week
-0.33%
1 month
0.33%
1 year
74.71%
YTD
29.36%
QTD
6.67%
Financial performance
How have Xeris Pharmaceuticals's revenue and profit performed over time
Revenue
$187.36M
Gross profit
$152.44M
Operating income
-$45.17M
Net income
-$63.11M
Gross margin
81.4%
Net margin
-33.7%
Xeris Pharmaceuticals's operating margin has increased by 25% YoY but it has decreased by 18% from the previous quarter
The company's revenue rose by 23% YoY and by 3.3% QoQ
The gross profit has grown by 22% YoY
The operating income has declined by 21% since the previous quarter but it has grown by 8% year-on-year
Growth
What is Xeris Pharmaceuticals's growth rate over time
Valuation
What is Xeris Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.55
XERS's EPS is down by 4.8% since the previous quarter but it is up by 2.2% year-on-year
XERS's equity is down by 47% since the previous quarter
XERS's price to sales (P/S) is 73% less than its 5-year quarterly average of 9.1 but 21% more than its last 4 quarters average of 2.0
The company's revenue rose by 23% YoY and by 3.3% QoQ
Efficiency
How efficient is Xeris Pharmaceuticals business performance
XERS's ROS is up by 26% year-on-year but it is down by 14% since the previous quarter
The return on invested capital has increased by 25% year-on-year but it has declined by 15% since the previous quarter
The return on assets has declined by 6% since the previous quarter and by 2.7% year-on-year
Dividends
What is XERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XERS.
Financial health
How did Xeris Pharmaceuticals financials performed over time
The total assets is 8% less than the total liabilities
XERS's quick ratio is down by 24% since the previous quarter and by 6% year-on-year
XERS's current ratio is down by 21% since the previous quarter
The debt to equity has plunged by 116% YoY but it has grown by 32% from the previous quarter
XERS's equity is down by 47% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.